Cleaner XT Rotational Thrombectomy: An Efficacious Endovascular Technique for Salvage of Thrombosed Arteriovenous Access and a 12 Month Outcome Analysis.

PURPOSE: This study aims to describe an efficacious method using Cleaner XT rotational thrombectomy with catheter-directed thrombolysis and drug-eluting balloon angioplasty for the salvage of thrombosed arteriovenous fistulae and grafts. MATERIALS AND METHODS: Retrospective analysis of all patients with thrombosed hemodialysis accesses who underwent endovascular salvage using the Cleaner XT rotational thrombectomy system at a single institution between June 2019 and September 2020 was performed. Patency was presented as Kaplan-Meier survival curves, and regression analysis was performed to examine predictors of postintervention primary patency and assisted primary patency based on Cox proportional-hazards model. RESULTS: Thirty-four patients with thrombosed accesses underwent Cleaner XT rotational thrombectomy between June 2019 and September 2020. Technical and clinical success were both 100%. Mean procedure time was 62 ± 20 minutes. Mean postintervention primary patency time was 152 ± 51 days; 30, 90, 180, and 365 day postintervention primary patency rates were 89%, 80%, 68%, and 56%, respectively. Mean postintervention-assisted primary patency time was 157 ± 59 days; 30, 90, 180, and 365 day postintervention-assisted primary patency rates were 91%, 82%, 71%, and 59%, and 180 and 365 day secondary patency rates were 97.2% and 94.4%, respectively. CONCLUSION: The Cleaner XT rotational thrombectomy device demonstrates excellent clinical and technical success rates, with good patency results at all time points up to 12 months postintervention.

Case Report of Ethanol and Cyanoacrylate Embolisation of a Recurrent Uncontrollable Torrentially Bleeding Arteriovenous Malformation of the Finger.

INTRODUCTION: In general, arteriovenous malformations (AVMs) are extremely rare, with an incidence of only 1 in 100,000. They are rarer still in the hands and present variably with bleeding, heaviness, a pulsatile mass, pain, ulceration, or necrosis. REPORT: The case of a 25 year old man with a rapidly bleeding right thumb AVM is presented. Bleeding was torrential and life threatening within a matter of seconds. He had previously undergone surgical ligation and embolisation twice at another centre, without success. At presentation, he had no thumb function and the bones of the thumb were exposed. An angio-embolisation was performed with ethanol and cyanoacrylate as the embolic agent. This was done using direct puncture into the AVM and also with a transarterial approach with microcatheters inserted into various unnamed branches feeding the AVM. Non-target embolisation and reflux was prevented by deploying a pneumatic tourniquet and mechanical elastic bands to confine the flow of the embolic agents within the AVM. Re-aspiration of the embolic agent post-embolisation was also performed to prevent local/systemic ethanol toxicity. Haemostasis was achieved without the need for further compression. A right thumb disarticulation was subsequently performed and the patient expressed great satisfaction with the outcome. DISCUSSION: AVMs in the hand are particularly challenging to treat owing to the need to preserve function of the myriad tissues and structural units that enable the many hand movements involved in activities of daily living. Even a partial loss of function may be disabling or poorly tolerated. The mainstays of treatment are embolisation, sclerotherapy, and surgical ligation/resection, all of which carry the potential for ischaemic injury to muscle and soft tissue. A holistic approach to management is desirable prior to selecting the appropriate management plan.

Studies of molecular mechanisms associated with increased deiodinase 3 expression in a case of consumptive hypothyroidism.

CONTEXT: Consumptive hypothyroidism (CH) is a rare form of hypothyroidism due to increased catabolic activity of type 3 iodothyronine deiodinase (DIO3) that can occur in large tumors. PATIENTs with CH typically present with markedly increased requirements for exogenous thyroid hormone and resolution after removal of the source of ectopic DIO3. DIO3 is encoded by DIO3, an imprinted gene expressed on the paternal allele that is located in a DIO3/delta-like 1 homolog (DLK1) gene locus regulated by a common control region, intergenic differentially methylated region (IGDMR). Because DIO3 is an imprinted gene, loss of imprinting at the IGDMR is thought to play a role in its increased expression; however, the molecular mechanism for DIO3 in CH currently is not known. OBJECTIVE: The aim of the study was to determine the molecular mechanism for CH in an adult patient. SETTING: The study was conducted in the Department of Endocrinology of a tertiary care center in Singapore. PATIENT: We report the case of an adult Asian female patient with a large intrathoracic fibrous tumor and severe hypothyroidism that resolved after tumor resection. RESULTS: The patient's tumor expressed increased levels of DIO3 and DLK1 mRNA and protein levels. Methylation-specific PCR of the IGDMR showed similar hypomethylation in placenta, thyroid, leukocytes, and tumor. Western blotting showed activation of sonic hedgehog (SHH) and MAPK signaling pathways that can increase DIO3 and DLK1 expression. CONCLUSIONS: Loss of imprinting did not account for overexpression of DIO3 in the patient's tumor. Instead SHH and MAPK/ERK pathway activation was associated with systemic thyroid hormone catabolism and growth of the tumor. These findings raise the possibility that other tumors that have increased SHH and MAPK/ERK signaling also may have intratumor or systemic effects on thyroid hormone function.